All posts tagged: treating

Repeated doses of psilocybin show promise for treating obsessive-compulsive disorder

Repeated doses of psilocybin show promise for treating obsessive-compulsive disorder

Published by José Betancourt

A new clinical trial suggests that multiple doses of psilocybin, the active compound in “magic mushrooms,” could provide substantial relief for individuals suffering from obsessive-compulsive disorder. The findings indicate that repeated weekly treatments are safe and tend to significantly reduce the severity of obsessive thoughts and compulsive behaviors. This research, published in the https://doi.org/10.1177/02698811261424214” target=”_blank”>Journal of Psychopharmacology, provides evidence for a new potential treatment avenue for those who have not found success with standard therapies. Obsessive-compulsive disorder is a debilitating psychiatric condition characterized by intrusive thoughts and repetitive behaviors. These symptoms consume a significant amount of time and can severely disrupt daily functioning. Current standard treatments typically include a combination of cognitive behavioral therapy and daily medications like serotonin reuptake inhibitors. However, these traditional approaches often fall short for many patients. People frequently experience delayed or incomplete symptom relief, and they sometimes struggle to adhere to the treatments due to unwanted side effects. Because of these challenges, scientists have sought alternative therapeutic approaches that might offer faster or more robust relief. Psilocybin has recently emerged …

Treating enterprise AI as an operating layer

Treating enterprise AI as an operating layer

Published by skeptic

At Ensemble, the strategy for addressing this challenge is knowledge distillation. The systematic conversion of expert judgment and operational decisions into machine-readable training signals. In health-care revenue cycle management, for example, systems can be seeded with explicit domain knowledge and then deepen their coverage through structured daily interaction with operators. In Ensemble’s implementation, the system identifies gaps, formulates targeted questions, and cross-checks answers across multiple experts to capture both consensus and edge-case nuance. It then synthesizes these inputs into a living knowledge base that reflects the situational reasoning behind expert-level performance. Turning decisions into a learning flywheel Once a system is constrained enough to be trusted, the next question is how it gets better without waiting for annual model upgrades. Every time a skilled operator makes a decision, they generate more than a completed task. They generate a potential labeled example—context paired with an expert action (and sometimes an outcome). At scale, across thousands of operators and millions of decisions, that stream can power supervised learning, evaluation, and targeted forms of reinforcement—teaching systems to behave …

The Met is Treating Lee Krasner as Pollock’s Equal—Will Market Follow?

The Met is Treating Lee Krasner as Pollock’s Equal—Will Market Follow?

Published by José Betancourt

Editor’s Note: This story originally appeared in On Balance, the ARTnews newsletter about the art market and beyond. Sign up here to receive it every Wednesday. The Metropolitan Museum of Art says its upcoming exhibition, “Krasner and Pollock: Past Continuous,” is a “story of equals.” Set to open in October, the survey brings together 120 works  by more than 80 lenders, with an explicit focus on considering Jackson Pollock and Lee Krasner “on their own terms” while also placing them in relation to one another.  Related Articles That is the museum’s version of the story. But the art market’s version is harsher, simpler, and much more familiar: Pollock remains one of the great trophies of 20th-century art. Krasner, his wife, widow, and interlocutor, and one of the most formidable painters of the New York School, still has to fight for every inch of price recognition. The price gap between these two long dead artists is sizeable: Pollock’s auction record sits at $61.2 million, while Krasner’s is just under 20 percent of that figure, at $11.7 million, set at Sotheby’s in 2019 …

Can an Artist Defeat a Dealer Treating Her Like a Pariah?

Can an Artist Defeat a Dealer Treating Her Like a Pariah?

Published by José Betancourt

With a world in crisis and an art market spinning out of control, ace art-world consultants Chen & Lampert deliver hard truths in response to questions sent by Art in America readers from far and wide. I fired my gallery of 25 years after they refused to release me from a contract that forbade me from selling my work anywhere else in the United States for two years. I was their top-selling artist for a while and tried negotiating, even offering a cut of sales, but they still refused. Leaving them was incredibly hard and felt like committing career suicide; but since then I’ve been doing great and am free to sell my work anywhere! But alas, there’s a new problem. I discovered that they damaged over $50,000 worth of my work and lied to the insurance company to avoid paying the claim. The gallery owner who made millions in sales off me is now acting like I am a pariah. He has also brought in other artists to copy my work. Does that seem normal, and am I …

A common antidepressant shows promise in treating methamphetamine dependence

A common antidepressant shows promise in treating methamphetamine dependence

Published by José Betancourt

Methamphetamine – more commonly known as meth, crystal or ice – is a highly addictive, stimulant drug. An estimated 7.4 million people in the world are dependent on it or “addicted” to it. They face multiple health risks including paranoia, feeling suicidal, heart problems, strokes, injuries from accidents, and a higher risk of early death. But there are no medications approved anywhere in the world to treat meth dependence. Now, a cheap, safe and readily available medicine that has been used to treat depression for years is showing promise. Our trial of mirtazapine, just published in JAMA Psychiatry, shows people who take it cut back their meth use. Few other options Australia has one of the highest number of people dependent on meth per capita worldwide. As there are no medications approved for meth dependence anywhere in the world, we have few treatment options. Currently available treatment options include counselling, detox or withdrawal and long-stay residential rehabilitation. However, access can be difficult and treatment dropout rates are high. Most people who go to rehab relapse. …

Treating Psychosis: Why We Aren’t Hearing Our Patients

Treating Psychosis: Why We Aren’t Hearing Our Patients

Published by Jenni Sidey

“If you don’t take the injection, your parents aren’t going to let you come home after what happened this week. You’ll be on the street,” I say to the young disheveled man in front of me. “If you don’t accept me as Jesus, your one true savior, you will burn in hell for all time.” Ben is looking at me with what seems to be the same concern I am feeling for him. “But Ben, what’s the harm in just taking it? I mean, what if I’m right, and you’re wrong? The stakes are so high for you.” I shudder, thinking of what will happen to this confused, gentle, psychotic kid if he truly becomes homeless on the streets of Philadelphia. “But if I’m right, and you’re wrong, you burn forever. The stakes are higher for you than they are for me.” Alone in the room with my patient, our realities clash. My version of Ben as a mentally ill young man on the precipice of homelessness is no more defendable to him than his …

A massive review reveals cannabis falls short in treating psychiatric disorders

A massive review reveals cannabis falls short in treating psychiatric disorders

Published by José Betancourt

Despite the rising popularity of medical cannabis for mental health and addiction, a new sweeping review shows little proof that these products actually help treat most of these conditions. The comprehensive analysis reveals that while cannabis-based medicines might offer mild relief for a handful of specific issues, they do not improve conditions like depression or anxiety and carry a greater risk of side effects. These findings were recently published in the journal The Lancet Psychiatry. Cannabinoids are the active chemical compounds found in the cannabis plant. The most well-known of these are tetrahydrocannabinol, which produces the high associated with marijuana, and cannabidiol, a non-intoxicating compound often sold as a wellness product. In recent years, an increasing number of people have turned to these substances to manage their mental health. In the United States and Canada, roughly 27 percent of people between the ages of 16 and 65 report using cannabis for medical reasons. About half of those individuals use it specifically to treat mental health struggles. In Australia, prescription approvals for cannabinoid medications have soared, …

A common antidepressant shows promise for treating post-orgasmic illness syndrome

A common antidepressant shows promise for treating post-orgasmic illness syndrome

Published by José Betancourt

A recent case report published in The Journal of Sexual Medicine details the experiences of two men who found relief from a rare, debilitating condition triggered by ejaculation. The patients, who suffered from severe flu-like and cognitive symptoms after orgasm, experienced major improvements after taking an antidepressant medication. These findings offer a potential therapeutic option for an illness that currently has no standard treatment. Post-orgasmic illness syndrome is a medical condition characterized by physical and cognitive symptoms that emerge shortly after a person experiences an orgasm. People with this condition often report extreme fatigue, muscle weakness, feverishness, and difficulty concentrating. These symptoms typically last anywhere from two to seven days, frequently causing individuals to avoid sexual activity entirely. The emotional toll of this condition can be severe. Men dealing with these symptoms often report low self-esteem, feelings of helplessness, and immense strain in their intimate relationships. Many patients internalize the blame for their sexual difficulties, believing that their physical or psychological makeup is fundamentally flawed. The exact biological mechanisms behind this illness remain poorly understood. …

Inside a Beirut hospital treating wounded children

Inside a Beirut hospital treating wounded children

Published by Sam Flores

IE 11 is not supported. For an optimal experience visit our site on another browser. UP NEXT Messages show Live Nation employees joking about fees 01:06 Alysa Liu welcomed back to Oakland as hometown hero 00:41 Hegseth says Iran’s leader is ‘likely disfigured’ 00:43 Gaza suffers food shortages as Iran war escalates 00:31 Explosion rocks Tehran during Quds Day rally 00:22 Noma chef René Redzepi resigns amid abuse allegations 00:50 Red fox stows away from England to New York on cargo ship 00:19 Pickup truck narrowly misses kids at bus stop in Maryland 00:14 Trump warns Iran’s World Cup team over safety in U.S. 00:38 U.S. KC-135 refueling plane crashes in Iraq 00:48 NASA says they knocked asteroid off its course 00:15 How AI is being used in the war with Iran 01:43 Sheriff says officials stand by Jewish community 00:18 Trump responds to attack on Michigan synagogue 00:28 Suspect dead in Michigan synagogue attack 01:03 Studies raise concerns about Black hair products 01:59 Police give updates on Michigan synagogue shooting 01:01 Iran’s new supreme …

Vibe coding with overeager AI: Lessons learned from treating Google AI Studio like a teammate

Vibe coding with overeager AI: Lessons learned from treating Google AI Studio like a teammate

Published by skeptic

Most discussions about vibe coding usually position generative AI as a backup singer rather than the frontman: Helpful as a performer to jump-start ideas, sketch early code structures and explore new directions more quickly. Caution is often urged regarding its suitability for production systems where determinism, testability and operational reliability are non-negotiable.  However, my latest project taught me that achieving production-quality work with an AI assistant requires more than just going with the flow. I set out with a clear and ambitious goal: To build an entire production‑ready business application by directing an AI inside a vibe coding environment — without writing a single line of code myself. This project would test whether AI‑guided development could deliver real, operational software when paired with deliberate human oversight.  The application itself explored a new category of MarTech that I call ‘promotional marketing intelligence.’ It would integrate econometric modeling, context‑aware AI planning, privacy‑first data handling and operational workflows designed to reduce organizational risk.  As I dove in, I learned that achieving this vision required far more than simple …